Theravance Biopharma And Pfizer Inc. Enter Global License Agreement For Skin-Targeted, Locally-Acting Pan-Janus Kinase Inhibitor Program; Theravance To Receive Upfront Cash Payment Of $10M And Up To $240M In Milestones
Benzinga Newsdesk